Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands

OBJECTIVE: To assess the cost effectiveness of cetuximab in third-line treatment of patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) in routine clinical practice compared with best supportive care (BSC). METHODS: Patients (n = 287) with KRAS wt mCRC treated with cetuximab or BSC...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Health Econ Rev
Hoofdauteurs: Uyl-de Groot, Carin A., van Rooijen, Elisabeth M., Punt, Cornelis J. A., Pescott, Chris P.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Springer Berlin Heidelberg 2018
Onderwerpen:
Review
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6049844/
https://ncbi.nlm.nih.gov/pubmed/30019286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13561-018-0197-3
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items